Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo

Journal of Antimicrobial Chemotherapy

Volumn 72, Issue 2, 2017, Pages 455-461

  Ammerman, Nicole C ^a,b   Swanson, Rosemary V ^b,c   Tapley, Asa ^a,b,d,e   Moodley, Chivonne ^b   Ngcobo, Bongani ^b   Adamson, John ^b   Dorasamy, Afton ^b   Moodley, Sashen ^b   Mgaga, Zinhle ^b,f   Bester, Linda A ^c   Singh, Sanil D ^c   Almeida, Deepak V ^a,b   Grosset, Jacques H ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^f HIV Vaccine Trials Network   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; ISONIAZID; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LUNG HOMOGENATE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TUBERCULOSIS; ANIMAL; BACTERIAL LOAD; BAGG ALBINO MOUSE; DRUG EFFECTS; LUNG; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL LOAD; CLOFAZIMINE; ISONIAZID; LUNG; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 85014556094     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw417     Document Type: Article

References (25)

1. WHO. Treatment of Tuberculosis: Guidelines-Fourth Edition. 2010. http://www.who.int/tb/publications/2010/9789241547833/en/.
2. Nuermberger EL. The role of the mouse model in the evaluation of new antituberculosis drugs. In: Donald PR, Van Helden PD, eds. Antituberculosis Chemotherapy. Basel: Karger, 2011; 145-52.
3. Mitchison DA. Basic concepts in the chemotherapy of tuberculosis. In: Gangadharam PRJ, Jenkins PA, eds. Mycobacteria Volume II Chemotherapy. New York: Chapman & Hall, 1998; 15-50.
4. Van Deun A, Maug AK, Salim MA et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-92.
5. Aung KJ, Van Deun A, Declercq E et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-7.
6. Piubello A, Harouna SH, Souleymane MB et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-94.
7. Kuaban C, Noeske J, Rieder HL et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 517-24.
8. Tang S, Yao L, Hao X et al. Clofazimine for the treatment of multidrugresistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60: 1361-7.
9. WHO. The Shorter MDR-TB Regimen. 2016. http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf.
10. Grosset JH, Tyagi S, Almeida DV et al. Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med 2013; 188: 608-12.
11. Tyagi S, Ammerman NC, Li SYet al. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis. Proc Natl Acad Sci USA 2015; 112: 869-74.
12. Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015; 191: 943-53.
13. Jindani A, Aber VR, Edwards EA et al. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-49.
14. Swanson RV, Adamson J, Moodley C et al. Pharmacokinetics and pharmacodynamics of clofazimine in the mouse model of tuberculosis. Antimicrob Agents Chemother 2015; 59: 3042-51.
15. Cholo MC, Steel HC, Fourie PB et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-8.
16. Yano T, Kassovska-Bratinova S, Teh JS et al. Reduction of clofazimine by mycobacterial type 2 NADH:Quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem 2011; 286: 10276-87.
17. Grosset J, Almeida D, Converse PJ et al. Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci USA 2012; 109: 15001-5.
18. Tasneen R, Li SY, Peloquin CA et al. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 2011; 55: 5485-92.
19. Banerjee DK, Ellard GA, Gammon PT et al. Some observations on the pharmacology of clofazimine (B663). Am J Trop Med Hyg 1974; 23: 1110-5.
20. de Steenwinkel JEM, de Knegt GJ, ten Kate MTet al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65: 2582-9.
21. Mothiba MT, Anderson R, Fourie B et al. Effects of clofazimine on planktonic and biofilm growth ofMycobacteriumtuberculosis and Mycobacterium smegmatis. J Glob Antimicrob Resist 2015; 3: 13-8.
22. Williams K, Minkowski A, Amoabeng O et al. Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 3114-20.
23. Swanson RV, Ammerman NC, Ngcobo B et al. Clofazimine contributes sustained antimicrobial activity after treatment cessation in the mouse model of tuberculosis chemotherapy. Antimicrob Agents Chemother 2016; 60: 2864-9.
24. Feng X, Zhu W, Schurig-Briccio LA et al. Antiinfectives targeting enzymes and the proton motive force. Proc Natl Acad Sci USA 2015; 112: E7073-82.
25. Lechartier B, Cole ST. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015; 59: 4457-63.